chevron_leftBack
As of 5 June 2026, HLB Genex, Inc. has a market cap of $57.75M USD, ranking #29569 globally and #1625 in South Korea.
It ranks #2679 in the Healthcare sector, and #514 in the Biotechnology industry.
Key Stats
Market Cap
$57.75MUSD
88.52B KRW
Enterprise Value
$73.33MUSD
112.39B KRW
Revenue (TTM)
$28.29MUSD
43.37B KRW
EBITDA (TTM)
$3.75MUSD
5.75B KRW
Net Income (TTM)
$14.74MUSD
22.59B KRW
EBITDA Margin
13%
Profit Margin
52%
PE Ratio
4.8
PS Ratio
2.0
PB Ratio
1.6
EV/EBITDA
20.3
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Eui-Joong Kim
open_in_new
Employees
75
Founded
2000
Website
hlbgenex.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 0% | -11% | 9.5% | 3% | -5.9% | -17% |
News
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
187420
에이치엘비제넥스(주)
ISIN: KR7187420005
Shares Out.:
Shares Outstanding:
32.554M1
Shares Float:
20.093M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
2,935 KRW |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About HLB Genex, Inc.
HLB Genex, Inc. engages in the research and development, production, import/export, and sale of enzymes and fermentation products in South Korea and internationally. Its industrial special enzyme products include lactase; catalase for use in semiconductor industry; and proteinase K for molecular diagnostics and genetic engineering experiments, as well as bio-health care ingredients comprise N-phytosphingosine and vitamin K2. The company also develops drug candidates for wet and dry macular degeneration, inflammatory bowel disease, anticancer, oral mucositis, nonalcoholic steatohepatitis, diabetic macular edema, and dry eye indications. The company was formerly known as GenoFocus, Inc. HLB Genex, Inc. was founded in 2000 and is based in Daejeon, South Korea.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
KRX: 207940
|
$44.48B
77K%
68.19T KRW
|
35.5
|
|
KRX: 068270
|
$27.89B
48K%
42.76T KRW
|
43.8
|
|
KRX: 196170
|
$13.27B
23K%
20.33T KRW
|
146.6
|
|
|
KRX: 028300
|
$5.46B
9K%
8.37T KRW
|
-
|
|
KRX: 087010
|
$3.96B
7K%
6.07T KRW
|
-
|
|
KRX: 302440
|
$2.23B
4K%
3.42T KRW
|
-
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NASDAQ: AMGN
|
$182.42B
316K%
|
23.9
|
|
NASDAQ: GILD
|
$159.92B
277K%
|
19.0
|
|
EBR: ARGX
|
$48.01B
83K%
41.39B EUR
|
39.9
|
|
ASX: CSL
|
$43.01B
74K%
60.27B AUD
|
29.3
|
|
SIX: LONN
|
$42.55B
74K%
33.71B CHF
|
37.2
|
|
NASDAQ: NTRA
|
$27.6B
48K%
|
-
|
chevron_leftBack